Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish Saxena

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
European Heart Journal. Digital Health|January 30, 2023
Using social media to recruit study participants for a randomized trial for hypertensionLida Feyz, Yale Wang, Atul Pathak, et al.
JAMA|February 16, 2024
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical TrialGeorge L Bakris, Manish Saxena, Anil Gupta, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 27, 2024
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIOMichael J Bloch, Ajay J Kirtane, Michel Azizi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 1, 2022
Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trialFlorian Rader, Ajay J Kirtane, Yale Wang, et al.
JAMA|May 28, 2025
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical TrialAkshay S Desai, Adam D Karns, Jolita Badariene, et al.
Journal of the American College of Cardiology|April 22, 2026
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical TrialAlberico L Catapano, Elina Mikhailova, Ann Marie Navar, et al.
JAMA|June 30, 2025
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical TrialManish Saxena, Luke Laffin, Claudio Borghi, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO StudyPhilippe Gosse, Antoine Cremer, Ajay J Kirtane, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|September 22, 2020
Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion CatheterStefan Bertog, Alok Sharma, Felix Mahfoud, et al.
Journal of Hypertension|August 26, 2021
Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trialNaomi D L Fisher, Ajay J Kirtane, Joost Daemen, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
European Heart Journal. Digital Health|January 30, 2023
Using social media to recruit study participants for a randomized trial for hypertensionLida Feyz, Yale Wang, Atul Pathak, et al.
JAMA|February 16, 2024
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical TrialGeorge L Bakris, Manish Saxena, Anil Gupta, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 27, 2024
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIOMichael J Bloch, Ajay J Kirtane, Michel Azizi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 1, 2022
Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trialFlorian Rader, Ajay J Kirtane, Yale Wang, et al.
JAMA|May 28, 2025
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical TrialAkshay S Desai, Adam D Karns, Jolita Badariene, et al.
Journal of the American College of Cardiology|April 22, 2026
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical TrialAlberico L Catapano, Elina Mikhailova, Ann Marie Navar, et al.
JAMA|June 30, 2025
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical TrialManish Saxena, Luke Laffin, Claudio Borghi, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO StudyPhilippe Gosse, Antoine Cremer, Ajay J Kirtane, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|September 22, 2020
Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion CatheterStefan Bertog, Alok Sharma, Felix Mahfoud, et al.
Journal of Hypertension|August 26, 2021
Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trialNaomi D L Fisher, Ajay J Kirtane, Joost Daemen, et al.
Pageof 7